Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers Aged 18-36 months: A phase 1 randomized-controlled clinical trial

Pediatric Infectious Disease Journal

Volumn 31, Issue 10, 2012, Pages 1061-1068

  Marshall, Helen S ^a   Richmond, Peter C ^b   Nissen, Michael D ^c   Jiang, Qin ^d   Anderson, Annaliesa S ^d   Jansen, Kathrin U ^d   Reynolds, Graham ^e   Ziegler, John B ^f   Harris, Shannon L ^d   Jones, Thomas R ^d   Perez, John L ^d  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d Pfizervaccine Research   (United States)

^e The Australian National University   (Australia)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

bactericidal antibodies; factor H binding protein; meningococcal vaccine; Neisseria meningitidis serogroup B; protein based vaccine antigens

Indexed keywords

ANTIHISTAMINIC AGENT; MENINGOCOCCUS VACCINE; PARACETAMOL; PLACEBO;

ANTIBODY RESPONSE; APPETITE; ARTICLE; ASTHMA; BACTERICIDAL ACTIVITY; CHILD; CHILDHOOD DISEASE; CONTROLLED STUDY; DIARRHEA; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE REACTION; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MENINGOCOCCOSIS; PHASE 1 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SIDE EFFECT; SLEEP; URTICARIA;

ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BLOOD BACTERICIDAL ACTIVITY; CHILD, PRESCHOOL; COMPLEMENT SYSTEM PROTEINS; DRUG TOXICITY; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFANT; MALE; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B; PLACEBOS; VACCINATION; VACCINES, SYNTHETIC;

EID: 84866632912     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31826327e4     Document Type: Article

References (24)

1. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningo-coccal disease. Vaccine. 2009;27(suppl 2):B51-B63.
2. Zollinger WD, Boslego J. Immunologic methods for diagnosis of infections by Gram-negative cocci. In: Rose NR, ed. Manual of Clinical Laboratory Immunology. 5th ed. Washington, DC: ASM Press; 1997:473-483.
3. European Centre for Disease Prevention and Control. Annual epidemiological report on communicable diseases in Europe. Stockholm 2010. Available at: http://ecdc.europa.eu/en/publications/publications/1011-sur- annual-epidemiological-report-on-communicable-diseases-in-europe.pdf. Accessed May 10, 2012.
4. Centers for Disease Control and Prevention. Active bacterial core surveillance report, emerging infections program network, Neisseria meningitidis, 2009. November 17, 2010. Available at: http://www.cdc.gov/abcs/ reportsfndings/survreports/mening09.pdf. Accessed May 10, 2012.
5. The Australian Meningococcal Surveillance Programme. Annual report of the Australian Meningococcal Surveillance Programme, 2009. Commun Dis Intell. 2010;34:291-320.
6. Pace D, Pollard AJ. Meningococcal A, C, Y and W-135 polysaccharide-pro- tein conjugate vaccines. Arch Dis Child. 2007;92:909-915.
7. UK Health Protection Agency. Meningococcal Reference Unit: isolates of Neisseria menengitidis; England and Wales, by serogroup & calendar year, 1998-2010. July 29, 2011. Available at: http://www.hpa.org.uk/web/ HPAweb&HPAwebStandard/HPAweb-C/1234859712887. Accessed May 10, 2012.
8. Trotter CL, Ramsay ME, Kaczmarski EB. Meningococcal serogroup C conjugate vaccination in England and Wales: coverage and initial impact of the campaign. Commun Dis Public Health. 2002;5:220-225.
9. Bruge J, Bouveret-Le Cam N, Danve B, et al. Clinical evaluation of a group B meningococcal N-propionylated polysaccharide conjugate vaccine in adult, male volunteers. Vaccine. 2004;22:1087-1096.
10. Girard M P, Preziosi M P, Aguado MT, et al. A review of vaccine research and development: meningococcal disease. Vaccine. 2006;24:4692-4700.
11. Jelfs J, Munro R, Wedege E, et al. Sequence variation in the porA gene of a clone of Neisseria meningitidis during epidemic spread. Clin Diagn Lab Immunol. 2000;7:390-395.
12. Tondella ML, Popovic T, Rosenstein NE, et al. Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The Active Bacterial Core Surveillance Team. J Clin Micro-biol. 2000;38:3323-3328.
13. Martin DR, Ruijne N, McCallum L, et al. The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specifc group B meningococcal vaccine MeNZB. Clin Vaccine Immunol. 2006;13:486-491.
14. Fletcher LD, Bernfeld L, Barniak V, et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun. 2004;72:2088-2100.
15. Masignani V, Comanducci M, Giuliani MM, et al. Vaccination against Neis-seria meningitidis using three variants of the lipoprotein GNA1870. J Exp Med. 2003;197:789-799.
16. Madico G, Welsch JA, Lewis LA, et al. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J Immunol. 2006;177:501-510.
17. Murphy E, Andrew L, Lee KL, et al. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis. 2009;200:379-389.
18. Jiang HQ, Hoiseth SK, Harris SL, et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine. 2010;28:6086-6093.
19. McNeil LK, Murphy E, Zhao XJ, et al. Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide. Vaccine. 2009;27:3417-3421.
20. Borrow R, Carlone GM, Rosenstein N, et al. Neisseria meningitidis group B correlates of protection and assay standardization-international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine. 2006;24:5093-5107.
21. Lucidarme J, Tan L, Exley RM, et al. Characterization of Neisseria menin-gitidis isolates that do not express the virulence factor and vaccine antigen factor H binding protein. Clin Vaccine Immunol. 2011;18:1002-1014.
22. Snape MD, Dawson T, Oster P, et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the frst year of life: a randomized comparative trial. Pediatr Infect Dis J. 2010;29:e71-e79.
23. Findlow J, Borrow R, Snape MD, et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis. 2010;51:1127-1137.
24. Anderson AS, Jansen KU, Eiden J. New frontiers in meningococcal vaccines. Expert Rev Vaccines. 2011;10:617-634.